- Telehealth Visits
Jennifer Michlitsch, MD
Pediatric Hematology-OncologyJennifer Michlitsch, MD
Pediatric Hematology-Oncology- Telehealth Visits
On this page
About me
Dr. Jennifer Michlitsch is a specialist in pediatric blood diseases whose focus is on caring for children with sarcomas, cancerous tumors in bone or other tissues. She has a special interest in treating patients with relapsed sarcomas and other childhood cancers.
Michlitsch's research focuses on new treatments for children with relapsed and treatment-resistant cancers. She has a particular interest in bringing these therapies to all patients at UCSF Benioff Children's Hospital Oakland, regardless of socioeconomic status.
Michlitsch earned her medical degree from the Keck School of Medicine of USC. She completed a residency in pediatrics at Children's Hospital Los Angeles and a fellowship in pediatric hematology and oncology at UCSF Benioff Children's Hospital Oakland.
Michlitsch is a member of the American Society of Pediatric Hematology/Oncology, Children's Oncology Group (COG) and COG's young investigator mentorship program.
Education
Board Certification
- Pediatric Hematology-Oncology, American Board of Pediatrics
Fellowship
- Ped. Hema/Oncology, UCSF Benioff Children's Hospital - Oakland GME
Residency
- Pediatrics, Childrens Hospital - Los Angeles GME
School
- MD, University of Southern California
Academic Title
- Health Sciences Clinical Professor
Care Keywords
Services
- Pediatric Hematology-Oncology
Locations
Provider Research Listing
Browse clinical trials and publications by this provider
Clinical trials
Pediatric Precision Laboratory Advanced Neuroblastoma TherapyOpens in a new window
Recruiting
To measure the response of treatments chosen based on: • Event free survival (EFS)Project: Every Child for Younger Patients With CancerOpens in a new window
Recruiting
The number of patients who agree to be in the Biobanking part of the study and have leftover tumor tissue and some normal blood, bone marrow, or other tissue s...Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell TumorsOpens in a new window
Recruiting
The time from study entry to the date of death, or date of last contact and ascertained as alive, whichever comes first.Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyOpens in a new window
Recruiting
Will compare in a randomized manner the post-induction 5-year EFS for children and young adults with High Risk (HR) B-cell acute lymphoblastic leukemia (B-ALL)...
Publications
Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here.
The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.